Outlook Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 18, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 18, 2026
OTLK$0.46+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| | |
| Exhibit Number | Description |
| 3.1 | Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024). |
| | |
| 3.2 | Certificate of Amendment of the Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed with the SEC on March 14, 2025) |
| | |
| 3.3 | Certificate of Amendment of the Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed with the SEC on July 16, 2026). |
| 3.4 | Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s current report on Form 8-K filed with the SEC on March 26, 2021). |
| | |
| 10.1+ | Note Purchase Agreement, dated March 16, 2026, by and between the Company and Atlas Sciences, LLC (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the SEC on March 16, 2026). |
| | |
| 10.2 | Note issued to Atlas Sciences, LLC, dated March 16, 2026 (incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K filed with the SEC on March 16, 2026). |
| | |
| | |
| 10.3 | Second Amendment, dated March 13, 2026, to the Convertible Promissory Note, dated March 13, 2025, by and between the Company and Avondale Capital, LLC (incorporated by reference to Exhibit 10.3 to the Company’s current report on Form 8-K filed with the SEC on March 16, 2026). |
| | |
| 10.4 | Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the SEC on March 25, 2026). |
| | |
| 10.5 | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Company’s current report on Form 8-K filed with the SEC on March 25, 2026). |
| | |
| 10.6 | Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the SEC on April 23, 2026). |
| | |
| 10.7 | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Company’s current report on Form 8-K filed with the SEC on April 23, 2026). |
| | |
| 10.8 | Form of Securities Purchase Agreement between Outlook Therapeutics, Inc. and the purchasers party thereto (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the SEC on April 23, 2026). |
| | |
| 10.9 | At the Market Offering Agreement between the Company and H.C. Wainwright & Co. LLC dated May 13, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the SEC on May 13, 2026). |
| | |
| 10.10 | Form of Warrant Amendment (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the SEC on May 28, 2026). |
| 10.11 | Form of Securities Purchase Agreement between Outlook Therapeutics, Inc. and the purchaser party thereto (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the SEC on May 28, 2026). |
| | |
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
| | |
| 31.2 | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. |
| | |
| 32.1* | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | |
| 32.2* | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | |
| 101.INS** | Inline XBRL Instance Document. |
| | |
| 101.SCH*** | Inline XBRL Taxonomy Extension Schema Document. |
| | |
| 101.CAL*** | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| | |
| 101.DEF*** | Inline XBRL Definition Linkbase Document. |
| | |
| 101.LAB*** | Inline XBRL Taxonomy Extension Labels Linkbase Document. |
| | |
| 101.PRE*** | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| | |
| 104** | Cover Page Interactive Data File. |
| * | Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. |
|---|
| ** | The XBRL Instance Document and Cover Page Interactive Data File do not appear in the Interactive Data File because their XBRL tags are embedded within the Inline XBRL document. |
|---|
| *** | Submitted electronically with the report. |
|---|
| + | Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.